Citations

Showing 10 of 108119 citations.

Development, validation, qualification, and dissemination of quantitative MR methods: Overview and recommendations by the ISMRM quantitative MR study group
Weingärtner, Sebastian , Desmond, Kimberly L. , Obuchowski, Nancy A. , Zhang, Yuxin , Biondetti, Emma , Ma, Dan , Golay, Xavier , Boss, Michael A. , Gunter, Jeffrey L. , Group, the ISMRM Quantitative MR Study, Zhang, Yuxin , Biondetti, Emma , Ma, Dan , Golay, Xavier , Boss, Michael A , Gunter, Jeffrey L , Keenan, Kathryn E , Hernando, Diego , Baeßler, Bettina , Keenan, Kathryn E. , Group, the ISMRM Quantitative MR Study

Mayo Clinic

Magnetic Resonance in Medicine | November 26, 2021 | Volume: 87 | Issue: 3 | Pages: 1184-1206

10.1002/mrm.29084 | PMID 34825741 Get It

On behalf of the International Society for Magnetic Resonance in Medicine (ISMRM) Quantitative MR Study Group, this article provides an overview of considerations for the development, validation, qualification, and dissemination of quantitative MR (qMR) methods. This process is framed in terms of two central technical performance properties, i.e., bias and precision. Although qMR is confounded by undesired effects, methods with low bias and high precision can be iteratively developed and validated. For illustration, two distinct qMR methods are discussed throughout the manuscript: quantification of liver proton‐density fat fraction, and cardiacT1. These examples demonstrate the expansion of qMR methods from research centers toward widespread clinical dissemination. The overall goal of this article is to provide trainees, researchers, and clinicians with essential guidelines for the development and validation of qMR methods, as well as an understanding of necessary steps and potential pitfalls for the dissemination of quantitative MR in research and in the clinic.
Correction of depression‐associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder
Federoff, Monica , McCarthy, Michael J. , Anand, Amit , Berrettini, Wade H. , Bertram, Holli , Bhattacharjee, Abesh Kumar, Calkin, Cynthia , Conroy, Carla , Coryell, William , D’Arcangelo, Nicole, DeModena, Anna, Fisher, Carrie, Feeder, Scott E., Frazier, Nicole, Frye, Mark A. , Gao, Keming , Glazer, Kara, Karberg, Toyomi, Harrington, Gloria, Kamali, Masoud , Kelly, Marisa , Leckband, Susan G. , Lohoff, Falk W. , Maihofer, Adam X. , McInnis, Melvin G. , Mondimore, Francis M. , Øedegaard, Ketil J. , Ritchey, Megan, Ryan, Kelly A. , Schinagle, Martha , Schoeyen, Helle K., Schwebel, Candice L. , Shaw, Martha, Shilling, Paul D. , Slaney, Claire , Stautland, Andrea , Tarwater, Bruce, Calabrese, Joseph R. , Zandi, Peter P. , Calkin, Cynthia V , Coryell, William , Feeder, Scott, Jakobsen, Petter , Nurnberger, John I , Alda, Martin , Nievergelt, Caroline M , Zandi, Peter P , Kelsoe, John R , Kamali, Masoud , Anand, Amit , McCarthy, Michael , McInnis, Melvin G , Garnham, Julie , Gershon, Elliot S. , Alliey‐Rodriguez, Ney , Goes, Fernando , Morken, Gunnar , Ritchey, Megan, Alda, Martin

Mayo Clinic

Bipolar Disorders | November 26, 2021 | Volume: 24 | Issue: 5 | Pages: 521-529

10.1111/bdi.13162 | PMID 34825444 Get It

AbstractBackgroundBipolar disorder (BD) is characterized by episodes of depression and mania and disrupted circadian rhythms. Lithium is an effective therapy for BD, but only 30%–40% of patients are fully responsive. Preclinical models show that lithium alters circadian rhythms. However, it is unknown if the circadian rhythm effects of lithium are essential to its therapeutic properties.MethodsIn secondary analyses of a multi‐center, prospective, trial of lithium for BD, we examined the relationship between circadian rhythms and therapeutic response to lithium. Using standardized instruments, we measured morningness, diurnal changes in mood, sleep, and energy (circadian rhythm disturbances) in a cross‐sectional study of 386 BD subjects with varying lithium exposure histories. Next, we tracked symptoms of depression and mania prospectively over 12 weeks in a subset of 88 BD patients initiating treatment with lithium. Total, circadian, and affective mood symptoms were scored separately and analyzed.ResultsSubjects with no prior lithium exposure had the most circadian disruption, while patients stable on lithium monotherapy had the least. Patients who were stable on lithium with another drug or unstable on lithium showed intermediate levels of disruption. Treatment with lithium for 12 weeks yielded significant reductions in total and affective depression symptoms. Lithium responders (Li‐Rs) showed improvement in circadian symptoms of depression, but non‐responders did not. There was no difference between Li‐Rs and nonresponders in affective, circadian, or total symptoms of mania.ConclusionsExposure to lithium is associated with reduced circadian disruption. Lithium response at 12 weeks was selectively associated with the reduction of circadian depressive symptoms. We conclude that stabilization of circadian rhythms may be an important feature of lithium's therapeutic effects. Clinical Trials Registry: NCT0127253.
Identifying group‐based patterns of suicidal ideation over the first 10 years after moderate‐to‐severe TBI
Klyce, Daniel W. , Perrin, Paul B. , Fisher, Lauren , Bergquist, Thomas F. , Wagner, Amy K. , Bombardier, Charles H. , Niemeier, Janet P. , Gary, Kelli W., Zafonte, Ross , Bombardier, Charles , Hammond, Flora M. , Juengst, Shannon B. , Rabinowitz, Amanda R. , Giacino, Joseph T.

Mayo Clinic

Journal of Clinical Psychology | November 26, 2021 | Volume: 78 | Issue: 5 | Pages: 877-891

10.1002/jclp.23282 | PMID 34825373 Get It

AbstractObjectiveTo identify group‐based patterns in suicidal ideation (SI) over the first 10 years after traumatic brain injury (TBI).MethodsParticipants included 9539 individuals in the TBI Model Systems National Database who responded to Patient Health Questionnaire‐9 Item 9 assessing SI at 1, 2, 5, and/or 10 years post‐injury. Ak‐means cluster analysis was conducted to determine group‐based patterns of SI, and pre‐injury variables were compared with ANOVAs and chi‐square tests.ResultsSI and attempts decreased over time. Four group‐based patterns emerged: Low, increasing, moderate, and decreasing SI. The low SI group comprised 89% of the sample, had the highest pre‐injury employment, fewer mental health vulnerabilities, least severe injuries, and were oldest. The increasing SI group had the most severe TBIs, were youngest, and disproportionately Black or Asian/Pacific Islander.ConclusionThese findings reinforce the importance of mental health and suicide risk assessment during chronic recovery from TBI.
Autoimmune conditions in the World Trade Center general responder cohort: A nested case‐control and standardized incidence ratio analysis
Sacks, Henry S. , Smirnoff, Margaret, Carson, Deborah A. , Cooney, Michael L. , Shapiro, Moshe , Hahn, Christopher J., Dasaro, Christopher R. , Crowson, Cynthia S. , Tassiulas, Ioannis, Hirten, Robert , Cohen, Benjamin L., Haber, Richard S., Crane, Michael A. , Harrison, Denise , Moline, Jacqueline , Udasin, Iris , Todd, Andrew C. , Teitelbaum, Susan L. , Crowson, Cynthia, Sloan, Nancy L , Davies, Terry F. , Simpson, David Martin , Luft, Benjamin J.

Mayo Clinic

American Journal of Industrial Medicine | November 26, 2021 | Volume: 65 | Issue: 2 | Pages: 117-131

10.1002/ajim.23313 | PMID 34825393 Get It

AbstractBackgroundThe World Trade Center (WTC) general responder cohort (GRC) was exposed to environmental toxins possibly associated with increased risk of developing autoimmune conditions.ObjectivesTwo study designs were used to assess incidence and risks of autoimmune conditions in the GRC.MethodsThree clinically trained professionals established the status of possible GRC cases of autoimmune disorders adhering to diagnostic criteria, supplemented, as needed, by specialists’ review of consenting responders’ medical records. Nested case‐control analyses using conditional logistic regression estimated the risk associated with high WTC exposure (being in the 9/11/2001 dust cloud or ≥median days' response worked) compared with low WTC exposure (all other GRC members'). Four controls were matched to each case on age at case diagnosis (±2 years), sex, race/ethnicity, and year of program enrollment. Sex‐specific and sensitivity analyses were performed. GRC age‐ and sex‐adjusted standardized incidence ratios (SIRs) were compared with the Rochester Epidemiology Project (REP). Complete REP inpatient and outpatient medical records were reviewed by specialists. Conditions meeting standardized criteria on ≥2 visits were classified as REP confirmed cases.ResultsSix hundred and twenty‐eight responders were diagnosed with autoimmune conditions between 2002 and 2017. In the nested case‐control analyses, high WTC exposure was not associated with autoimmune domains and conditions (rheumatologic domain odds ratio [OR] = 1.03, 95% confidence interval [CI] = 0.77, 1.37; rheumatoid arthritis OR = 1.12, 95% CI = 0.70, 1.77). GRC members had lower SIR than REP. Women's risks were generally greater than men's.ConclusionsThe study found no statistically significant increased risk of autoimmune conditions with WTC exposures.
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , D’Angelica, Michael I. , Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Burgoyne, Adam M. , Chahal, Prabhleen , Chang, Daniel T. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon, Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Reddy, Sanjay S. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Stein, Stacey , Yopp, Adam C. , McMillian, Nicole R., Hochstetler, Cindy, Darlow, Susan, Sahai, Vaibhav , Anders, Robert A. , Bachini, Melinda , Borad, Mitesh J. , Glazer, Evan S. , Goyal, Lipika , Hawkins, William G , Levine, Matthew H , Raman, Steven S. , Vauthey, Jean‐Nicolas , Venook, Alan P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 26, 2021 | Volume: 19 | Issue: 5 | Pages: 541-565

10.6004/jnccn.2021.0022 | PMID 34030131 Get It

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients
Mellors, Patrick , Kourelis, Taxiarchis , Muchtar, Eli , Gertz, Morie A. , Kumar, Shaji , Kapoor, Prashant , Lacy, Martha Q. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Warsame, Rahma , Lin, Yi , Siddiqui, Mustaqeem , Kyle, Robert A. , Mellors, Patrick W , Muchtar, E , Gertz, Morie A , Kumar, Shaji K , Hwa, Yi L , Warsame, Rahma , Leung, Nelson , Gonsalves, Wilson , Rajkumar, S Vincent , Dispenzieri, Angela , Siddiqui, Mustaqeem A , Dingli, David , Lin, Yi , Go, Ronald S. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | November 26, 2021 | Volume: 97 | Issue: 2 | Pages: 209-215

10.1002/ajh.26422 | PMID 34822175 Get It

AbstractThromboses are prevalent in POEMS syndrome, but few risk factors for POEMS‐associated thrombosis have been identified. The objective of this study is to identify novel risk factors for POEMS‐associated thrombosis. In this retrospective cohort of 230 POEMS patients, 27% developed thrombosis. Arterial events were slightly more common than venous. Stroke accounted for 26% of all thromboses and 53% of arterial events. There were differences in baseline features between the thrombosis group and the no thrombosis group, and these were driven by patients with arterial thrombosis. Risk factors for arterial thrombosis included thrombocytosis, elevated hemoglobin/hematocrit, extravascular volume overload, and splenomegaly. Hyperprolactinemia appeared to be a risk factor for venous thrombosis. The risk of thrombosis was most striking among men with elevated hemoglobin (32% vs. 5%, p < .001) and hematocrit (42% vs. 5%, p < .001) compared to men without. Most thromboses occurred prior to POEMS directed therapy, and most that occurred during therapy happened within 3 months of diagnosis. Twenty‐one percent of patients with thrombosis had recurrence. In recognition of high overall rates of thrombosis in this population, all patients with POEMS syndrome should receive prophylactic antiplatelet therapy, and clinicians should consider anticoagulation in patients with risk factors for POEMS‐associated thrombosis.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Thompson, John A. , Albertini, Mark R. , Barker, Christopher A. , Baumgartner, Joel , Boland, Genevieve M. , DiMaio, Dominick J. , Durham, Alison B. , Fleming, Martin D. , Galan, Anjela , Gastman, Brian , Grossmann, Kenneth F. , Guild, Samantha, Holder, Ashley M. , Johnson, Douglas B. , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Sosman, Jeffrey A. , Wuthrick, Evan , McMillian, Nicole R., Engh, Anita M. , Swetter, Susan M. , Chmielowski, Bartosz , Fields, Ryan C. , Joseph, Richard W. , Margolin, Kim , Olszanski, Anthony J. , Salama, April K.S. , Sharma, Rohit R. , Boland, Genevieve

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 26, 2021 | Volume: 19 | Issue: 4 | Pages: 364-376

10.6004/jnccn.2021.0018 | PMID 33845460 Get It

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modifications of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Association of ≥ 12 months of delayed surgical treatment for cervical myelopathy with worsened postoperative outcomes: a multicenter analysis of the Quality Outcomes Database
Asuzu, David T. , Yun, Jonathan , Alvi, Mohammed Ali , Chan, Andrew K. , Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Park, Paul , Meyer, Scott A., Asher, Anthony L. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurosurgery: Spine | November 26, 2021 | Volume: 36 | Issue: 4 | Pages: 568-574

10.3171/2021.7.spine21590 | PMID 34740180 Get It

OBJECTIVE Degenerative cervical myelopathy (DCM) results in significant morbidity. The duration of symptoms prior to surgical intervention may be associated with postoperative surgical outcomes and functional recovery. The authors’ objective was to investigate whether delayed surgical treatment for DCM is associated with worsened postoperative outcomes. METHODS Data from 1036 patients across 14 surgical centers in the Quality Outcomes Database were analyzed. Baseline demographic characteristics and findings of preoperative and postoperative symptom evaluations, including duration of symptoms, were assessed. Postoperative functional outcomes were measured using the Neck Disability Index (NDI) and modified Japanese Orthopaedic Association (mJOA) scale. Symptom duration was classified as either less than 12 months or 12 months or greater. Univariable and multivariable regression were used to evaluate for the associations between symptom duration and postoperative outcomes. RESULTS In this study, 513 patients (49.5%) presented with symptom duration < 12 months, and 523 (50.5%) had symptoms for 12 months or longer. Patients with longer symptom duration had higher BMI and higher prevalence of anxiety and diabetes (all p < 0.05). Symptom duration ≥ 12 months was associated with higher average baseline NDI score (41 vs 36, p < 0.01). However, improvements in NDI scores from baseline were not significantly different between groups at 3 months (p = 0.77) or 12 months (p = 0.51). Likewise, the authors found no significant differences between groups in changes in mJOA scores from baseline to 3 months or 12 months (both p > 0.05). CONCLUSIONS Surgical intervention resulted in improved mJOA and NDI scores at 3 months, and this improvement was sustained in both patients with short and longer initial symptom duration. Patients with DCM can still undergo successful surgical management despite delayed presentation.
High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases
Juran, Brian D., Cheung, Angela , Schlicht, Erik M., Liang, Yongliang , Niedzwiecki, Megan M. , Walker, Douglas Ian , Liang, Yongliang, LaRusso, Nicholas F. , Gores, Gregory J. , Jones, Dean P. , Miller, Gary W. , Lazaridis, Konstantinos N.

Mayo Clinic

Hepatology Communications | November 26, 2021 | Volume: 6 | Issue: 5 | Pages: 965-979

10.1002/hep4.1871 | PMID 34825528 Get It

Progress in development of prognostic and therapeutic options for the rare cholestatic liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), is hampered by limited knowledge of their pathogeneses. In particular, the potential role of hepatotoxic and/or metabolism‐altering environmental chemicals in the pathogenesis of these diseases remains relatively unstudied. Moreover, the extent to which metabolic pathways are altered due to ongoing cholestasis and subsequent liver damage or possibly influenced by hepatotoxic chemicals is poorly understood. In this study, we applied a comprehensive exposomics‐metabolomics approach to uncover potential pathogenic contributors to PSC and PBC. We used untargeted high‐resolution mass spectrometry to characterize a wide range of exogenous chemicals and endogenous metabolites in plasma and tested them for association with disease. Exposome‐wide association studies (EWAS) identified environmental chemicals, including pesticides, additives and persistent pollutants, that were associated with PSC and/or PBC, suggesting potential roles for these compounds in disease pathogenesis. Metabolome‐wide association studies (MWAS) found disease‐associated alterations to amino acid, eicosanoid, lipid, co‐factor, nucleotide, mitochondrial and microbial metabolic pathways, many of which were shared between PSC and PBC. Notably, this analysis implicates a potential role of the 5‐lipoxygenase pathway in the pathogenesis of these diseases. Finally, EWAS × MWAS network analysis uncovered linkages between environmental agents and disrupted metabolic pathways that provide insight into potential mechanisms for PSC and PBC. Conclusion: This study establishes combined exposomics‐metabolomics as a generalizable approach to identify potentially pathogenic environmental agents and enumerate metabolic alterations that may impact PSC and PBC, providing a foundation for diagnostic and therapeutic strategies.
Development of pemphigus vulgaris after the second dose of the mRNA‐1273 SARS‐Cov‐2 vaccine
Koutlas, Ioannis G. , Camara, Renee, Davis, Mark D.P. , Miller, Daniel D. , Davis, Mark Denis P., Argyris, Prokopios P.

Mayo Clinic

Oral Diseases | November 26, 2021 | Volume: 28 | Issue: S2 | Pages: 2612-2613

10.1111/odi.14089 | PMID 34825752 Get It